Page 2457 - Williams Hematology ( PDFDrive )

2428 Index Index 2429

Erythrocyte antigens (Cont.): automated analysis, 13–16 functions of, 104–105
diseases associated with, 2340, 2341–2342t, collection by apheresis, 2368 life span, 104
2342–2343 composition, 469 nucleated, 47–48
enzymes/chemicals affecting, 2339 carbohydrates, organic acids, and organelle removal in, 478
expression, 104, 2336–2337, 2340 metabolites, 471t pocked (pitted), 468
genetics, 2339 coenzyme and vitamins, 470t in polycythemia vera, 1295
immunogenicity, 2336 electrolytes, 471t precursor cell kinetics, 75t
protein, 2337 nucleotides, 470t precursors, 463–465, 463f, 464f, 465f
serologic detection, 2348–2350, 2349t, phospholipids, 469t production. See Erythropoiesis
2350t protein and water content, 469t progenitors, 463
Erythrocyte binding-like antigen, 815 concentration of, in clonal hematopoietic splenic clearance/sequestration, 90–91
Erythrocyte enzyme disorders, 689–712. disorders, 1284–1285 viscosity, 668
See also specific enzymes deformability, 469–471, 499 Erythrocyte zinc protoporphyrin, 635
clinical features, 708–710, 876 destroyed, fate of, 499–500, 500f Erythrocytosis. See Polycythemia
course and prognosis, 712 destruction/turnover, 495–500. See also (erythrocytosis)
definition and history, 689–690 Hemolysis Erythroderma, history of, 6
differential diagnosis, 711 in anemia of inflammation, 550 Erythroid cells
epidemiology, 690, 690f in situ localization of, 496–498, 497f heme synthesis in, 895–896
etiology and pathogenesis, 691–699, 876 measurement of, 495–496, 496f marrow, 34
genetics, 699–708 mechanisms of, 498–499, 619 Erythroid colony cultures
laboratory features, 710–711 senescence and, 497–498 in polycythemia diagnosis, 882
therapy, 711–712 disorders in polycythemia vera, 1296
Erythrocyte membrane, 661–669, 662f anemia. See Anemia Erythroid Kruppel-like factor (EKLF), 484
altered surface properties, 499 from chemical or physical agents, Erythroid/megakaryopoietic progenitors, 271
damage to, 809 809–811 Erythroid progenitors, 271, 463
deformability, 668 enzyme. See Erythrocyte enzyme Erythroleukemia, 1390
ion transport and exchange channels, 668, disorders Erythromelalgia, 1293, 1294f, 1308, 2080
669f fragmentation. See Hemolytic anemia, Erythron, 461. See also Erythrocytes
lipids, 662 fragmentation Erythrophagocytosis, 619, 1050f
in newborn, 104–105 membrane. See Erythrocyte membrane Erythropoiesis, 508f
organization, 667–668 disorders androgens and, 560
permeability, 669, 669f paroxysmal nocturnal hemoglobinuria. anemia and, 505–506
proteins. See Membrane proteins See Paroxysmal nocturnal in anemia of inflammation, 551–552
stability, 668 hemoglobinuria (PNH) effective, 489–490
Erythrocyte membrane disorders, 21f polycythemia (erythrocytosis). See embryonic and fetal, 480
acanthocytosis, 680–681 Polycythemia erythroblast enucleation in, 481–482
cryohydrocytosis, 682t, 684 fetal, antigen development on, 2337–2338 ferrokinetics, 490–491, 490f, 491t
familial deficiency of high-density hemoglobin and, 479–480 hepcidin regulation by, 622
lipoproteins, 684 inclusions, 467–468, 468f history of, 479
hereditary elliptocytosis. See Hereditary iron deficiency and, 633, 633f, 634f ineffective, 490
elliptocytosis (HE) life span, 495 as cause of iron overload, 641
hereditary pyropoikilocytosis. See marrow, 34 lead and, 811
Hereditary pyropoikilocytosis (HPP) mass measurement, 488–489, 882, 1295 measurements, 489–491
hereditary spherocytosis. See Hereditary membrane. See Erythrocyte membrane megaloblastic anemia and, 597
spherocytosis (HS) metabolism, 691–699 microRNAs in, 487–488
laboratory features, 670f, 671f antioxidant enzymes, 698–699 neonatal, 102–105
neuroacanthocytosis. See glucose phylogeny, 479–480
Neuroacanthocytosis enzymes, 692t, 694–697 precursor cells in, 481, 482f, 482t, 483f
protein defects, 670t pathways, 692–694, 693f progenitor cells in, 32.2–3, 480f
Rh-deficiency syndrome, 684 glutathione, 698 regulation, 482–487, 504f
Southeast Asian ovalocytosis, 680 nucleotide, 699 deterministic model of lineage
stomatocytosis. See Stomatocytosis morphology, 21, 21 commitment, 483, 483f
Erythrocytes in marrow infiltration, 658, 659f erythropoietin in, 484
aged, 134, 471, 473, 497–498 pathophysiology of, 472–473t, 473, 475 erythropoietin receptor in, 484–485, 486f
antibodies. See Erythrocyte antibodies structure and shape, 468–469, 468f hypoxia-inducible factors in, 486–487,
antigens. See Erythrocyte antigens neonatal, 102–105, 103t 486f

Kaushansky_index_p2393-2506.indd 2428 9/21/15 3:21 PM